Business

Biotech, pharma, and money in science

Fred Hutchinson Cancer Research Center
Business

How life sciences companies are using AI — and how to separate hope from hype

By Rebecca Robbins, Adam Feuerstein, and Damian Garde

Genetic Testing Immigration
Biotech

Could genetic testing help reunite separated immigrant families? It’s complicated

By Rebecca Robbins

Business

How can Atul Gawande help reinvent health care with his new company? These people have some ideas

By Justin Chen

Atul Gawande Innovation
Business

Five ideas that might steer Gawande as CEO of Amazon-backed health company

By Andrew Joseph and Megan Thielking

Health

Can this doctor figure out how to stop Alzheimer’s before it starts?

By Joshua Kendall

Dr. Atul Gawande
Business

Surgeon Atul Gawande selected as CEO of new health care company from Amazon, partners

By Andrew Joseph

Biotech

Startups aim to make allies of human gut’s microbes

By Jonathan Saltzman — Boston Globe

Lamar Alexander 340B
Politics

Key lawmaker calls for more scrutiny of hospitals using drug discount program — but no broader changes

By Erin Mershon

In the Lab

Archived chat: last week in CRISPR — cancer, patents, and a dip in the market

By Sharon Begley

Sarepta
Biotech

With tantalizing early results, Sarepta’s gene therapy for Duchenne raises hopes for ‘real change’

By Adam Feuerstein

Elizabeth Holmes Theranos
Business

7 questions to watch after criminal charges filed in the Theranos saga

By Rebecca Robbins and Damian Garde

Red blood cells
Adam's Take

Geron wants J&J to continue a drug development partnership, but new data weaken its case

By Adam Feuerstein

Eric Schmidt
Biotech

CAR-T startup Allogene Therapeutics picks up veteran analyst Eric Schmidt as CFO

By Adam Feuerstein

Kaleo Naloxone Donation 02
Exclusive

Donations of $4,500 overdose antidote were PR gold for drug maker — but some kits were close to expiring

By Max Blau

Exclusive

Citing weak demand, IBM Watson Health to scale back hospital business

By Casey Ross and Ike Swetlitz

Sickle cell Bluebird Update
Biotech

New Bluebird data show promising benefits for gene therapy, if they last

By Adam Feuerstein

Chuck Grassley CREATES
Politics

Bill to encourage generic-drug development passes a key hurdle

By Erin Mershon

Cellular Authophagy
Business

Is it time to target autophagy to treat disease? 

By Elizabeth Cooney

Sick Watson
Exclusive

IBM Watson Health hampered by internal rivalries and disorganization, former employees say

By Casey Ross and Ike Swetlitz

Jennifer Doudna
Business

The University of California will finally be granted a key CRISPR patent

By Sharon Begley

Fatty Liver Drawing
Adam's Take

Questionable data aside, Galmed Pharma soars in a fatty liver stock bubble

By Adam Feuerstein

Pharmaceuticals
Politics

Azar says HHS could change or eliminate Medicare drug rebates without Congress

By Ike Swetlitz and Erin Mershon

Sad child
Biotech

Sage Therapeutics gets ‘go faster’ permission from FDA on oral depression drug

By Adam Feuerstein

In the Lab

A serious new hurdle for CRISPR: Edited cells might cause cancer, two studies find

By Sharon Begley

IBM Watson
Business

IBM’s problems with Watson Health run deeper than recent layoffs, former employees say

By Casey Ross and Ike Swetlitz

Biotech

For smaller companies, a presence at BIO conference is a big deal

By Jonathan Saltzman — Boston Globe

Ebola Vaccines
Business

Move by China could undermine Merck, Johnson & Johnson efforts on Ebola vaccine

By Helen Branswell

Chest X-ray pneumonia
Adam's Take

Proteostasis cystic fibrosis drug disappoints, easing competitor concerns for Vertex Pharma

By Adam Feuerstein

Hong Kong Stocks
Biotech

Can Hong Kong lure biotech without inflating a bubble?

By Rebecca Robbins

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy